Gambogic Acid Sensitizes Ovarian Cancer Cells to Doxorubicin Through ROS-Mediated Apoptosis

Cell Biochemistry and Biophysics

Volumn 67, Issue 1, 2013, Pages 199-206

  Wang, Jianxia ^a   Yuan, Zhixiang ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Sichuan Academy of Chinese Medicine Sciences   (China)

Author keywords

Doxorubicin; Gambogic acid; Ovarian cancer; ROS; Synergistic effect

Indexed keywords

MUS;

ANTINEOPLASTIC AGENT; CASPASE 3; DOXORUBICIN; GAMBOGIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; XANTHONE DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES; TRANSPLANTATION, HETEROLOGOUS; XANTHONES;

EID: 84883456542     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9534-7     Document Type: Article

References (50)

1. Posadas, E. M., Davidson, B., & Kohn, E. C. (2004). Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Current Opinion in Oncology, 16, 478-484.
2. Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer statistics, 2010. CA: A Cancer Journal for Clinicians, 60, 277-300.
3. Ozols, R. F. (2005). Treatment goals in ovarian cancer. International Journal of Gynecological Cancer, 15(Suppl 1), 3-11.
4. Ozols, R. F., Bookman, M. A., Connolly, D. C., et al. (2004). Focus on epithelial ovarian cancer. Cancer Cell, 5, 19-24.
5. Landen, C. N, Jr, Birrer, M. J., & Sood, A. K. (2008). Early events in the pathogenesis of epithelial ovarian cancer. Journal of Clinical Oncology, 26, 995-1005.
6. Carvalho, C., Santos, R. X., Cardoso, S., et al. (2009). Doxorubicin: the good, the bad and the ugly effect. Current Medicinal Chemistry, 16, 3267-3285.
7. Campos, S. M., Penson, R. T., Mays, A. R., et al. (2001). The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecologic Oncology, 81, 206-212.
8. Prasad, S., Pandey, M. K., Yadav, V. R., & Aggarwal, B. B. (2011). Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer prevention research (Philadelphia, Pa.), 4, 1084-1094.
9. Bharti, A. C., & Aggarwal, B. B. (2002). Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemosensitization. Annals of the New York Academy of Sciences, 973, 392-395.
10. Panthong, A., Norkaew, P., Kanjanapothi, D., et al. (2007). Anti-inflammatory, analgesic and antipyretic activities of the extract of gamboge from Garcinia hanburyi Hook f. Journal of Ethnopharmacology, 111, 335-340.
11. Yang, Y., Yang, L., You, Q. D., et al. (2007). Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Letters, 256, 259-266.
12. Zhang, H. Z., Kasibhatla, S., Wang, Y., et al. (2004). Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorganic & Medicinal Chemistry, 12, 309-317.
13. Liu, W., Guo, Q. L., You, Q. D., et al. (2005). Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World Journal of Gastroenterology, 11, 3655-3659.
14. Gu, H., Wang, X., Rao, S., et al. (2008). Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Molecular Cancer Therapeutics, 7, 3298-3305.
15. Guo, Q. L., You, Q. D., Wu, Z. Q., et al. (2004). General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacologica Sinica, 25, 769-774.
16. Pandey, M. K., Sung, B., Ahn, K. S., et al. (2007). Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood, 110, 3517-3525.
17. Yi, T., Yi, Z., Cho, S. G., et al. (2008). Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Research, 68, 1843-1850.
18. Yu, J., Guo, Q. L., You, Q. D., et al. (2007). Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis, 28, 632-638.
19. Wang, J., Liu, W., Zhao, Q., et al. (2009). Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology, 256, 135-140.
20. Zou, Z. Y., Wei, J., Li, X. L., et al. (2012). Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells. Cancer Biotherapy and Radiopharmaceuticals, 27, 299-306.
21. Huang, H., Chen, D., Li, S., et al. (2011). Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Letters, 301, 221-228.
22. Gerlier, D., & Thomasset, N. (1986). Use of MTT colorimetric assay to measure cell activation. Journal of Immunological Methods, 94, 57-63.
23. Iwasa, T., Okamoto, I., Takezawa, K., et al. (2010). Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. British Journal of Cancer, 103, 36-42.
24. Lee, M. H., Choi, B. Y., Kundu, J. K., et al. (2009). Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Research, 69, 7449-7458.
25. Ding, L., Huang, D., Wang, J., & Li, S. (2007). Determination of gambogic acid in human plasma by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 846, 112-118.
26. Colombo, P. E., Boustta, M., Poujol, S., et al. (2011). Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer. Gynecologic Oncology, 122, 632-640.
27. Chou, T. C., & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27-55.
28. Kim, K. K., Kawar, N. M., Singh, R. K., et al. (2011). Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines. Gynecologic Oncology, 122, 183-189.
29. Nie, F., Zhang, X., Qi, Q., et al. (2009). Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology, 260, 60-67.
30. Swift, L. P., Rephaeli, A., Nudelman, A., et al. (2006). Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Research, 66, 4863-4871.
31. Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology, 57, 727-741.
32. Osone, S., Hosoi, H., Kuwahara, Y., et al. (2004). Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells. International Journal of Cancer, 112, 219-224.
33. Mansouri, A., Ridgway, L. D., Korapati, A. L., et al. (2003). Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. Journal of Biological Chemistry, 278, 19245-19256.
34. Naumann, R. W., & Coleman, R. L. (2011). Management strategies for recurrent platinum-resistant ovarian cancer. Drugs, 71, 1397-1412.
35. Wang, J., & Zhou, Z. (2007). Phase I human tolerability trial of gambogic acid. Chinese Journal of New Drugs, 16, 79-82.
36. Gu, H., Rao, S., Zhao, J., et al. (2009). Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. Journal of Cancer Research and Clinical Oncology, 135, 1777-1782.
37. Zhao, L., Guo, Q. L., You, Q. D., et al. (2004). Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biological & Pharmaceutical Bulletin, 27, 998-1003.
38. Xu, X., Liu, Y., Wang, L., et al. (2009). Gambogic acid induces apoptosis by regulating the expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells. International Journal of Dermatology, 48, 186-192.
39. Rong, J. J., Hu, R., Song, X. M., et al. (2010). Gambogic acid triggers DNA damage signaling that induces p53/p21(Waf1/CIP1) activation through the ATR-Chk1 pathway. Cancer Letters, 296, 55-64.
40. Wang, T., Wei, J., Qian, X., et al. (2008). Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Letters, 262, 214-222.
41. Chen, J., Gu, H. Y., Lu, N., et al. (2008). Microtubule depolymerization and phosphorylation of c-Jun N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma MCF-7 cells. Life Sciences, 83, 103-109.
42. Li, R., Chen, Y., Zeng, L. L., et al. (2009). Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells. Toxicology, 262, 98-105.
43. Thannickal, V. J., & Fanburg, B. L. (2000). Reactive oxygen species in cell signaling. American Journal of Physiology. Lung Cellular and Molecular Physiology, 279, L1005-L1028.
44. Trachootham, D., Alexandre, J., & Huang, P. (2009). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature Reviews Drug Discovery, 8, 579-591.
45. Sinha, B. K., Mimnaugh, E. G., Rajagopalan, S., & Myers, C. E. (1989). Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Research, 49, 3844-3848.
46. Staedler, D., Idrizi, E., Kenzaoui, B. H., & Juillerat-Jeanneret, L. (2011). Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemotherapy and Pharmacology, 68, 1161-1172.
47. Uguz, A. C., Cig, B., Espino, J., et al. (2012). Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. Journal of Pineal Research, 53, 91-98.
48. Das, A., Durrant, D., Mitchell, C., et al. (2010). Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proceedings of the National Academy of Sciences USA, 107, 18202-18207.
49. Saitoh, M., Nishitoh, H., Fujii, M., et al. (1998). Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO Journal, 17, 2596-2606.
50. Guo, Q., Qi, Q., You, Q., et al. (2006). Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic & Clinical Pharmacology & Toxicology, 99, 178-184.